Congratulations to New Mexico’s Second Cohort of Innovators!
Filtravate is developing a membrane to filter out viruses. Their advanced manufacturing process is sustainable, uses less energy and isn’t as solvent intensive, lowering the cost of production. The low production costs and high-performance features make Filtravate’s membranes ideal for monoclonal antibody (mAb) production applications by solving the industries two biggest challenges: need low-cost bioprocess and increased demand for portable single use mAb bioprocess systems.
To unlock the potential of the lunar economy and the next iteration of space exploration and development, Space Kinetic has developed a new way of transferring energy and material resources in low gravity environments using one integrated system. Their Kinetic Distribution System for energy distribution can transfer materials 200 times faster than rover-based methods. Plug-and-play functionality and strong network effects will allow our kinetic grid to scale quickly to create a durable human presence on the moon.
Cohort 1 Fellows
Cliff Chan
OAM Photonics LLC pursues the development of a compact solid-state coherent optical sensor for long-distance 3D light detection and ranging (LiDAR) with numerous applications including 3D topographic mapping, advanced driver-assistance (ADAS), and autonomous driving. The vision of OAM Photonics is to build novel, smarter and less expensive optical sensors enabled by electronic-photonic integrated circuit (EPIC) technology.
Blue Eye Soft is building its Space Anomaly Forensics & Environment Resolution (SAFER) platform to fuse and analyze volumes of historic data to develop predictions of space weather impacts. The NM LEEP collaboration will match Los Alamos’ expertise and capabilities in predicting the behavior of relativistic electrons within the whole outer Van Allen belt with Blue Eye Soft’s predictive analytics and data resources to create the first of its kind forecasting model that provides space weather forecasts to operators and predicts likely radiation damage to satellites impacted by these storms.
Kristina Trujillo
T-NeuroPharma is taking a new approach to Alzheimer’s Disease (AD) diagnosis and treatment. T-Neuro is developing a biomarker to detect early AD in both clinical trial and clinical laboratory settings. Ideally, the biomarker will be utilized to detect the disease early, then the treatment will be administered to prevent the disease from ever progressing. T-Neuro is initially focused on first developing the biomarker for use in clinical trials and in clinical testing laboratories. The development of the therapeutic will follow in Stage II of the Development plan.
We support projects that change our world for the better.
“NM LEEP presents a unique opportunity for Los Alamos National Laboratory and our community to support deep-tech innovators and entrepreneurs.”
-Thom Mason, director of Los Alamos National Laboratory.
Stay Connected
Sponsors and Partners of New Mexico LEEP
